tiprankstipranks
Surmodics (SRDX)
NASDAQ:SRDX
Holding SRDX?
Track your performance easily

SurModics (SRDX) Stock Price & Analysis

111 Followers

SRDX Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Earnings And GrowthSRDX's revenue growth, excluding SurVeil license fee revenue, improved to 17% in F4Q24 from 9% in F3Q24.
Financial PerformanceSurmodics’ Q4 financial results were quite strong relative to the modeling as well as the consensus, with total revenue of $33.2 million, a significant increase compared to the same period a year ago.
Medical Device RevenueThe medical device unit accounted for $25.8 million in revenue, reflecting a substantial growth of 22.2%.
Bears Say
Acquisition ProcessThe pending acquisition of Surmodics by GTCR has been delayed due to a request for additional information from the United States Federal Trade Commission, extending the waiting period.
Acquisition UncertaintyThere is a pending acquisition of SRDX by a private equity firm.
Regulatory RisksIf the GTCR transaction were ultimately blocked by the FTC, SRDX would be entitled to a regulatory termination fee, indicating potential complications in the acquisition process.
---

Financials

Annual

Ownership Overview

4.14%16.70%0.86%65.75%
0.86% Other Institutional Investors
65.75% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

SRDX FAQ

What was Surmodics’s price range in the past 12 months?
Surmodics lowest stock price was $25.17 and its highest was $42.44 in the past 12 months.
    What is Surmodics’s market cap?
    Surmodics’s market cap is $523.74M.
      When is Surmodics’s upcoming earnings report date?
      Surmodics’s upcoming earnings report date is Jan 30, 2025 which is in 10 days.
        How were Surmodics’s earnings last quarter?
        Surmodics released its earnings results on Nov 06, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.293 by $0.163.
          Is Surmodics overvalued?
          According to Wall Street analysts Surmodics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Surmodics pay dividends?
            Surmodics does not currently pay dividends.
            What is Surmodics’s EPS estimate?
            Surmodics’s EPS estimate is -0.12.
              How many shares outstanding does Surmodics have?
              Surmodics has 14,294,147 shares outstanding.
                What happened to Surmodics’s price movement after its last earnings report?
                Surmodics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.293. Following the earnings report the stock price went up 2.204%.
                  Which hedge fund is a major shareholder of Surmodics?
                  Among the largest hedge funds holding Surmodics’s share is Gamco Investors, Inc. ET AL. It holds Surmodics’s shares valued at 6M.
                    ---

                    Company Description

                    Surmodics

                    SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
                    ---

                    SRDX Earnings Call

                    Q2 2024
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The earnings call highlighted strong revenue growth and profitability improvements, driven by the Medical Device segment and successful product launches. However, challenges remain in the IVD segment and product gross margins. The sentiment is positive due to the significant achievements outweighing the challenges.Read More>
                    ---
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Conmed
                    Orthofix
                    Atricure
                    Merit Medical Systems
                    Lemaitre Vascular
                    Staar Surgical
                    Popular Stocks
                    ---
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis